Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 721 to 735 of 8398 results

  1. COVID-19 prescribing briefing: corticosteroids

    Dexamethasone and hydrocortisone are both corticosteroids; they have a role in treating COVID-19 in certain people.

  2. Suicide prevention

    All NICE products on suicide prevention. Includes any guidance and quality standards.

  3. Infectious disease prevention and control

    All NICE products on infectious disease prevention and control. Includes any guidance, advice and quality standards.

  4. Accident and injury prevention

    All NICE products on accident and injury prevention. Includes any guidance, advice and quality standards.

  5. Lymphoedema

    All NICE products on lymphoedema. Includes any guidance and advice.

  6. Vaginal conditions

    All NICE products on vaginal conditions. Includes any guidance.

  7. Mesothelioma

    All NICE products on mesothelioma. Includes any guidance.

  8. Maxillofacial conditions

    All NICE products on maxillofacial conditions. Includes any guidance.

  9. Gastroparesis

    All NICE products on gastroparesis. Includes any guidance and advice.

  10. Diabetes

    All NICE products on diabetes. Includes any guidance, advice and quality standards.

  11. Kidney cancer (QS215)

    This quality standard covers diagnosing and managing renal cell carcinoma in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

  12. Ectopic pregnancy and miscarriage (QS69)

    This quality standard covers the diagnosis and initial management of ectopic pregnancy and miscarriage in women in their first trimester (up to 13 completed weeks of pregnancy). It includes assessment and diagnosis for women with suspected early pregnancy loss. It describes high-quality care in priority areas for improvement.

  13. Parathyroid disorders

    All NICE products on parathyroid disorders. Includes any guidance.

  14. Serious eye disorders (QS180)

    This quality standard covers the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD) and the prevention of sight loss. It describes high-quality care in priority areas for improvement.

  15. Mitapivat for treating pyruvate kinase deficiency (terminated appraisal) (TA867)

    NICE is unable to make a recommendation on mitapivat (Pyrukynd) for treating pyruvate kinase deficiency in adults because Agios did not provide an evidence submission. We will review this decision if the company decides to make a submission.

    Sections for TA867